TempraMed Technologies (FRA:9DY) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


FRA:9DY TempraMed Technologies Ltd FRA:9DY
1 GF Score
Price €0.30
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies ROE % Adjusted to Book Value?

TempraMed Technologies FRA:9DY -14.16% 1 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates FRA:9DY with a GF Score™ of 1/100. The stock has 5 warning signs investors should review.

TempraMed Technologies's ROE % for the quarter that ended in Mar. 2026 was 0.00%. TempraMed Technologies's PB Ratio for the quarter that ended in Mar. 2026 was N/A. TempraMed Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

TempraMed Technologies ROE % Adjusted to Book Value Related Terms

TempraMed Technologies ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies ROE % Adjusted to Book Value Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:9DY vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, TempraMed Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TempraMed Technologies ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TempraMed Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TempraMed Technologies's ROE % Adjusted to Book Value falls into.


FRA:9DY
1GF Score
TempraMed Technologies Ltd FRA:9DY
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies ROE % Adjusted to Book Value Calculation

TempraMed Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

TempraMed Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
TempraMed Technologies (FRA:9DY) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TempraMed Technologies and its competitors.
Is TempraMed Technologies' ROE % Adjusted to Book Value too high?
TempraMed Technologies' current ROE % Adjusted to Book Value is 0.00%. Overall, TempraMed Technologies has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' ROE % Adjusted to Book Value compare to ABT and SYK?
TempraMed Technologies' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TempraMed Technologies and its competitors. TempraMed Technologies's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. TempraMed Technologies' overall GF Score™ is 1/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
1GF Score

Get the complete analysis for FRA:9DY

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price